Myofascial Pain Syndrome and Plantar Fasciitis Treatment

Sponsor
Istanbul Training and Research Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT06023836
Collaborator
(none)
66
1
2
4.3
15.5

Study Details

Study Description

Brief Summary

Patients with plantar fasciitis between the ages of 25-65 years who presented to the Physical Medicine and Rehabilitation clinic with the complaint of heel pain and met the inclusion and exclusion criteria will be included in the study. Demographic data (age, gender, body mass index, symptom duration) will be recorded at the beginning of the study. Then, Foot Functional Index (FFI) and Visual Analog Scale (VAS) scales will be recorded. Participants will be randomly divided into two groups. Group 1 will receive dry needling and Group 2 will receive extracorporeal shock wave therapy (ESWT). Patients in the 1st group will undergo 3 sessions of dry needling with Seirin branded 0.6*50 mm acupuncture needles at one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles. Patients in the 2nd group will receive 3 sessions of ESWT (MASTERPLUS MP 200 ENERGY 2 brand ESWT device) with a frequency of 12-15 Hz, 2-3 bars and 2500 pulses once a week. ESWT will be applied to the 5 most sensitive points of the plantar fascia with equal shares of 2500 pulses.

Condition or Disease Intervention/Treatment Phase
  • Device: ESWT
  • Procedure: Dry needling
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
66 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants will be randomly divided into 2 groups and will be treated with ESWT or Dry needling.Participants will be randomly divided into 2 groups and will be treated with ESWT or Dry needling.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Myofascial Pain Syndrome in Plantar Fasciitis; Comparison of Dry Needling and Extracorporeal Shockwave Therapy (ESWT) Effects on Pain and Function
Actual Study Start Date :
May 1, 2023
Anticipated Primary Completion Date :
Aug 28, 2023
Anticipated Study Completion Date :
Sep 8, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: group 1: ESWT treatment

Participants in this group will only receive ESWT treatment

Device: ESWT
Patients in the group will receive 3 sessions of ESWT (MASTERPLUS MP 200 ENERGY 2 brand ESWT device) with a frequency of 12-15 Hz, 2-3 bars and 2500 pulses once a week. ESWT will be applied to the 5 most sensitive points of the plantar fascia with equal shares of 2500 pulses.

Active Comparator: Dry needling

Participants in this group will only receive Dry needling treatment

Procedure: Dry needling
Dry needling with Seirin branded 0.6*50 mm acupuncture needles will be performed for 3 sessions with one week intervals for the trigger point detected by manual palpation in the medial gastrocnemius, lateral gastrocnemius, soleus, flexor digitorum brevis, quadratus plantae, abductor hallucis brevis muscles of the patients in the group.

Outcome Measures

Primary Outcome Measures

  1. Pain was evaluated with a Visual analog scale (VAS) score. [5 months]

    VAS score ranges from 0 to 10. Comparison of the effects of ESWT and dry needling on pain in the management of plantar fasciitis

  2. Function was evaluated with (Foot Functional Index) FFI score. [5 months]

    Comparison of the effects of ESWT and dry needling on function in the management of plantar fasciitis

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged 25-65 years with heel pain for more than 6 weeks

  • tenderness on palpation in the medial calcaneal region

  • aggravation of symptoms while standing and in the first hours of the morning

  • who agreed not to receive anti-inflammatory treatment during the study period

  • fascia thickness >4mm measured by ultrasound.

Exclusion Criteria:
  • Patients diagnosed with rheumatologic diseases

  • Those diagnosed with Diabetes Mellitus (DM), those with chronic liver and kidney failure

  • Anti-inflammatory-analgesic treatment within the last 1 month

  • Diagnosed with inflammatory rheumatic disease

  • Those with a history of foot surgery

  • Those with mid or hindfoot deformity

  • Previous history of central or peripheral nerve damage, lower extremity neuropathy

  • Those diagnosed with Diabetes Mellitus

  • Those with cognitive impairment

  • Unassisted mobilization

  • Those with bleeding disorders

  • Pregnant women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Istanbul Training and Resarch Hospital Istanbul Turkey

Sponsors and Collaborators

  • Istanbul Training and Research Hospital

Investigators

  • Principal Investigator: Burak Tayyip Dede, İstanbul Training and Research Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Burak Tayyip Dede, Medical Doctor, Istanbul Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT06023836
Other Study ID Numbers:
  • 07/04/2023; 2011-KAEK-50;89
First Posted:
Sep 5, 2023
Last Update Posted:
Sep 5, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Burak Tayyip Dede, Medical Doctor, Istanbul Training and Research Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 5, 2023